ライフサイエンスコーパス: protease inhibitor

1 adhesion molecule, and HAI-2, a cell surface protease inhibitor.

2 e peptide from the alpha1-antitrypsin serine protease inhibitor.

3 cies had prenatal TDF exposure and 6% used a protease inhibitor.

4 hism that impacts simeprevir, another NS3/4A protease inhibitor.

5 Trypsin was strongly inhibited by serine protease inhibitor.

6 l small molecule that is used worldwide as a protease inhibitor.

7 chronic kidney disease (CKD) as use of older protease inhibitors.

8 protein of HIV-1 variants resistant to HIV-1 protease inhibitors.

9 mechanism for the antimicrobial activity by protease inhibitors.

10 ligands for a variety of highly potent HIV-1 protease inhibitors.

11 everse transcriptase inhibitors (NRTIs), and protease inhibitors.

12 proving the resistance profile of HCV NS3/4A protease inhibitors.

13 assessed in the presence/absence of specific protease inhibitors.

14 d robust classification of resistance to HIV protease inhibitors.

15 avenues for a systematic discovery of serine protease inhibitors.

16 activity relationship studies for optimizing protease inhibitors.

17 d autoproteolytic activity and inhibition by protease inhibitors.

18 ingly need second-line regimens with boosted protease inhibitors.

19 ls with a ROS scavenger N-acetyl cysteine or protease inhibitors.

20 combination of HIV reverse transcriptase and protease inhibitors.

21 hree different classes of potential covalent protease inhibitors.

22 nsights for optimizing these promising HIV-1 protease inhibitors.

23 RT inhibitors (NRTIs), and 3.6% to 5.2% for protease inhibitors.

24 ations of HCV NS5A antivirals but not by NS3 protease inhibitors.

25 ly, the largest and most ubiquitous group of protease inhibitors.

26 Deletion of the gene that encodes serine protease inhibitor 1 (SPI-1) of rabbitpox virus and vacc

27 pathologic enzyme activation (such as serine protease inhibitor 1) have been found in familial forms

28 on of the deleted C12L gene, encoding serine protease inhibitor 1, enhances replication of MVA in hum

29 reverse transcriptase inhibitors (3.0%) and protease inhibitors (1.9%).

30 gimen of grazoprevir (MK-5172; an HCV NS3/4A protease inhibitor; 100 mg/day) plus ruzasvir (MK-8408;

31 rand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%).

32 of patients harbor a mutation in the serine protease inhibitor 1A (SERPINA1) gene leading to a singl

33 The function of serine protease inhibitor 2A (Spi2A) was studied in mouse TH2 c

34 mer (-)-6 has been converted to potent HIV-1 protease inhibitor 3.

35 Selective pressure exerted by HIV-1 protease inhibitors, a mainstay of current anti-HIV-1 th

36 A mixture of bacterial protease inhibitors abrogated the effect of MET-1 effect

37 in the asthma groups were defence response, protease inhibitor activity, inflammatory and calcium si

38 The Ser protease inhibitor AEBSF (4-[2-aminoethyl] benzene sulfo

39 r Microcystis abundances but did up-regulate protease inhibitors (aer and mcn gene sets) and microcys

40 Genetic mutations predispose the serine protease inhibitor alpha(1)-antitrypsin to misfolding an

41 IgE-tp interact with polymers of the serine protease inhibitor alpha-1-antitrypsin (A1AT).

42 Protease inhibitors ameliorated the ability of MC(TC)LUV

43 hat peptidomimetic FISLE-412,1 a reduced HIV protease inhibitor analogue, was well-tolerated, altered

44 vir is a fixed-dose combination of an NS3/4A protease inhibitor and an NS5A inhibitor approved for th

45 weeks of response-guided therapy with an NS3 protease inhibitor and dual NS5A inhibitor-NS5B nucleoti

46 SerpinB1, a protease inhibitor and neutrophil survival factor, was r

47 n stored baseline samples in patients in the protease inhibitor and NRTI group and calculated the pre

48 vailable in 391 (92%) of 426 patients in the protease inhibitor and NRTI group.

49 mpared with 312 (81%) of 383 patients in the protease inhibitor and raltegravir group at week 144 (p=

50 of pH and temperature, as well as effect of protease inhibitors and chosen metal ions on the aminope

51 ammatory responses (S100 proteins, alarmins, protease inhibitors); and glycolysis and antioxidant def

52 ng minimally discussed, including vicilin, a protease inhibitor, and a flavonol synthase/flavanone 3-

53 Era of listing was divided into interferon, protease inhibitor, and direct-acting antiviral.

54 ts in cohort A remained on their second-line protease inhibitor, and had the most participants with g

55 ses in serum IL-8, IL-6, secretory leukocyte protease inhibitor, and regenerating islet-derived prote

56 , circulating immunoglobulin complex, serine protease inhibitors, and microtubule bundle formation pa

57 overy of the first potent ubiquitin-specific protease inhibitors, and the maturation of proteolysis t

58 HIV-1 protease inhibitors are crucial for treatment of HIV-1/A

59 raction areas between protease-substrate and protease-inhibitor are shared, the two interactions are

60 n NS5A inhibitor) and grazoprevir (an NS3/4A protease inhibitor) are direct-acting antiviral agents r

61 n NS5A inhibitor) and grazoprevir (an NS3/4A protease inhibitor) are direct-acting antiviral agents r

62 rive the development of potent and selective protease inhibitors as novel drugs for influenza treatme

63 ound prenatal combination ART with a boosted protease inhibitor associated with increased risk of pre

64 nanoparticles containing the antiretroviral protease inhibitor atazanavir.

65 omplexes led us to the identification of the protease inhibitor AtSerpin1.

66 s studied in mouse TH2 cells, and the serine protease inhibitor B3 (SERPINB3) and SERPINB4 genes were

67 progression, AGRN (agrin), SERPINB5 (serine protease inhibitor B5), and CSTB (cystatin B).

68 pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor based on a P1-P3 macrocyclic tripepti

69 icitabine and tenofovir disoproxil fumarate (protease inhibitor based regimen); regimens were masked

70 ase inhibitor regimen and 286 to receive the protease inhibitor based regimen.

71 (RR, 1.01; P = .78), and current ART class (protease inhibitor based vs nonnucleoside inhibitor base

72 A focused library of serine protease inhibitors based on diaryl phosphonate warheads

73 r-based (1563, 95% CI 1432-1707) vs. boosted protease inhibitor-based (1890, 95% CI 1704-2095; P = .0

74 onulin levels increased with RAL compared to protease inhibitor-based regimens (week 96, P = .02); mi

75 Protease inhibitor-based regimens in children aged <3 ye

76 al studies to assess the efficacy of boosted protease inhibitor-based regimens in low-income and midd

77 to overcome barriers to scaling up pediatric protease inhibitor-based regimens in sub-Saharan Africa

78 with HIV-1C, especially in those on boosted protease inhibitor-based regimens.

79 s per mL or more after more than 24 weeks of protease inhibitor-based second-line ART.

80 ight not accurately predict NRTI activity in protease inhibitor-based second-line ART.

81 cimen, clinicians were directed to prescribe protease inhibitor-based second-line ART.

82 patients with HCV genotype 1 who had failed protease inhibitor-based triple therapy, and in 4 of 4 (

83 was similar across ARV regimens (P = .774): protease inhibitor-based, 97% (95% confidence interval [

84 Protease nexin-1 (PN-1) is a serine protease inhibitor belonging to the serpin superfamily.

85 synthesis of a complex target of HCV NS3/4a protease inhibitor BI 201420 was accomplished.

86 A serine protease inhibitor blocked peptide and oligosaccharide h

87 ral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available

88 obulin-like protein 1 (A2ML1) is a monomeric protease inhibitor but has the hydroxyl reactivity-conve

89 A serine protease inhibitor but not inhibitors of cysteine protea

90 tigated the role of hydroxyl reactivity in a protease inhibitor by comparing recombinant WT A2ML1 and

91 athways and allows the identification of new protease inhibitors by genome mining.

92 d to improve the resistance profile of HIV-1 protease inhibitors by optimizing hydrogen bonding and v

93 lymph prophenoloxidase (proPO), regulated by protease inhibitors called serpins.

94 xperimental results suggesting that NS5A- or protease-inhibitors can generate non-infectious virus, w

95 The enriched protease inhibitors CER-based protein extract resulted i

96 L. tomentosa contained no lectins or protease inhibitors (chymotrysin and trypsin) and 12 pol

97 minogen activator inhibitor-1 (PAI-1; serine protease inhibitor, clade E, member 1), connective tissu

98 ir (NS5A inhibitor) and paritaprevir (NS3/4A protease inhibitor; co-dosed with ritonavir) plus ribavi

99 imilar to controls in plasma collected using protease inhibitors cocktail (PIC), but they significant

100 ntinuation of ritonavir-boosted lopinavir (a protease inhibitor commonly used in low-income and middl

101 py with more ART regimens, and longer use of protease inhibitors, compared with Prevotella-rich MSM.

102 Crystal structures of protease-inhibitor complexes revealed strong hydrogen bo

103 Protease inhibitor-containing ART was associated with in

104 n-NRTIs and confirmed virologic failure on a protease inhibitor-containing regimen were required.

105 The cysteine protease inhibitor cystatin C is internalized by some ca

106 In contrast, the cysteine protease inhibitor cystatin C was expressed only in tubu

107 , raltegravir, elvitegravir, bictegravir), 2 protease inhibitors (darunavir, atazanavir), and 2 nonnu

108 of potent small-molecule non-peptidic dengue protease inhibitors derived from 4-benzyloxyphenylglycin

109 Viruses resistant to NS3-4A protease inhibitors disappear from peripheral blood in a

110 NS5A inhibitor, and paritaprevir, an NS3/4A protease inhibitor dosed with ritonavir, plus ribavirin

111 ey subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS pa

112 om off-target interactions of HIV (aspartyl) protease inhibitor drugs with Ste24.

113 omplex is resistant to regulation by protein protease inhibitors during prothrombin activation.

114 alities similar to that seen with a cysteine protease inhibitor, E-64 (I-1).

115 Importantly, the cysteine protease inhibitor E64 prevented mucous degradation, muc

116 amide versus continuing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disopro

117 308 and the Study of the Consequences of the Protease Inhibitor Era (SCOPE) cohort showed no viremia

118 servational Study of the Consequences of the Protease Inhibitor Era) cohort, a clinic-based cohort of

119 way and alpha1-antitrypsin protein (a serine protease inhibitor) expression and downregulation of neu

120 g mutations known to cause resistance to HIV protease inhibitors faithfully recapitulated the reporte

121 ER with the MEROPS resource for protease and protease inhibitor families.

122 biquitously-expressed member of the cysteine protease inhibitor family that is present at notably hig

123 tors (BBIs) are a well-known family of plant protease inhibitors first described 70 years ago.

124 ve research has led to a variety of approved protease inhibitors for the treatment of HIV/AIDS.

125 vely, these results indicate that a cysteine protease inhibitor from bacterial origin could be a suit

126 ed for the efficient recovery of patatin and protease inhibitors from potato pulp.

127 p-Met-Asp-Phe-NH(2)), and whether the use of protease inhibitors further improves CCKR2 targeting.

128 treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pi

129 week 48 compared with 231 (81%) women in the protease inhibitor group (adjusted difference 6.5%; 95%

130 e NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C

131 he NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C

132 cleoside polymerase-inhibitor (GS-9669) or a protease-inhibitor (GS-9451) and after 12 weeks with sof

133 h HIV-1C who were given therapy with boosted protease inhibitors had earlier time-to-secondary virolo

134 of RASs known to confer resistance to other protease inhibitors had little to no impact on voxilapre

135 Meanwhile, other protease inhibitors had no impact on precursor autoproce

136 caused by mutations in SPINT2, encoding the protease inhibitor HAI-2, and is characterized by severe

137 Since HIV protease inhibitors have "off target" cellular effects,

138 A significant number of protease inhibitors have also been shown to possess anti

139 e of their S proteins for entry, a number of protease inhibitors have been proposed as antiviral agen

140 Several small molecule MALT1 protease inhibitors have recently been described that co

141 he absence of the cognate Kunitz-type serine protease inhibitors, hepatocyte growth factor activator

142 Inhibitors of the HIV aspartyl protease [HIV protease inhibitors (HIV-PIs)] are the cornerstone of tr

143 tage antiplasmodial activity of the aspartic protease inhibitor hydroxyl-ethyl-amine-based scaffold c

144 periodontopathogen that expresses miropin, a protease inhibitor in the serpin superfamily.

145 es between drug sensitivity or resistance to protease inhibitors in patient-derived samples.

146 emical and viral mechanisms of resistance to protease inhibitors in patients with non-B subtypes of H

147 rs, the AlphaLISA assay confirmed all 11 HIV protease inhibitors in the library capable of suppressin

148 criptase inhibitors plus 1 ritonavir-boosted protease inhibitor, in naive and paired HIV-1/O vs HIV-1

149 ck for several clinical and experimental HIV protease inhibitors including the highly important drug

150 nown family of aldehyde-containing, peptidic protease inhibitors, including antipain, chymostatin, le

151 rss4-deficient mice varied in sensitivity to protease inhibitors, indicating that different, but over

152 inistration attenuated both EAE symptoms and protease inhibitor induction potentially by decreasing i

153 governed by numerous protease-substrate and protease-inhibitor interactions whose conservation is cr

154 e follicle wall was prevented by infusion of protease inhibitors into the ovarian bursa.

155 performance of (177)Lu-DOTA-PP-F11N without protease inhibitors is as good as the performance of (17

156 mbalance between NSP activity and endogenous protease inhibitors is associated with chronic inflammat

157 ce that benzyloxyphenylglycine in flaviviral protease inhibitors is positioned in the prime site of t

158 wman-Birk inhibitor (BBI), a soybean-derived protease inhibitor, is known to have anti-inflammatory e

159 tigma protein with homology with Kunitz-type protease inhibitors, is essential to SI in Nicotiana spp

160 rated by a three-step synthesis of the known protease inhibitor K11777.

161 Degradation of the protective serine protease inhibitor Kazal type 1 (SPINK1) by mesotrypsin

162 ere we show that tumor-cell-expressed serine protease inhibitor Kazal type 1 (SPINK1) is a key driver

163 The loss-of-function mutations of serine protease inhibitor, Kazal type 1 (SPINK1) gene are assoc

164 This enzyme cleaved the tripeptide aldehyde protease inhibitors, leading to the formation of "pro-py

165 omly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100

166 riant is located in the gene encoding serine protease inhibitor, low levels of which are associated w

167 Notably, Indinavir; an HIV protease inhibitor, may be effective in reducing the vir

168 ase inhibitor apilimod(2-4) and the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825 and O

169 e testing); or with raltegravir; or alone as protease inhibitor monotherapy (discontinued after week

170 Protease inhibitor monotherapy (PIM) for human immunodef

171 otease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir inducti

172 p=0.02) and 233 (61%) of 280 patients in the protease inhibitor monotherapy group at week 96 (p<0.000

173 sified to combination therapy after week 96; protease inhibitor monotherapy group).

174 In the protease inhibitor monotherapy group, 292 (78%) of 375 h

175 50% effective concentration against NS3 from protease inhibitor-naive patient samples ranged from 0.3

176 ible inhibition of RD21 activity by a Kunitz protease inhibitor named water-soluble chlorophyll-bindi

177 logically recapitulated by combining the HIV-protease inhibitor nelfinavir with ISRIB, an experimenta

178 targeted by fungal effector Avr2, a secreted protease inhibitor of the fungal pathogen Cladosporium f

179 High abundance proteins like protease inhibitors of plasma display a multitude of int

180 Serine protease inhibitors of the Kunitz-bovine pancreatic tryp

181 e results indicate a conserved function of a protease inhibitor on cell death regulators from differe

182 ass spectrometry to study the effects of HIV protease inhibitors on the human zinc metalloprotease ZM

183 her, we analyzed the effects of actinonin, a protease inhibitor, on obstetrical injury of the vaginal

184 s of C57/BL6J-betaENaC-Tg mice with a serine protease inhibitor ONO-3403, a derivative of camostat me

185 tive viral particles by treatment with HIV-1 protease inhibitors or by genetic manipulation of gag.

186 glecaprevir/pibrentasvir and use of boosted protease inhibitors or efavirenz is not recommended.

187 ) were associated with more weight gain than protease inhibitors or non-nucleoside reverse transcript

188 s associated with more weight gain than were protease inhibitors or nonnucleoside reverse transcripta

189 Serine protease inhibitors, or serpins, are paradigms for this

190 this study, the roles of rice bran cysteine protease inhibitors, oryzacystatins, were considered for

191 Extensive studies on resistance to viral protease inhibitors, particularly those of HIV-1 and hep

192 rom 345 DAA-naive or -experienced (including protease inhibitor) patients and 344 genotype 1 to 6 rep

193 Biodistribution without and with the protease inhibitors phosphoramidon and thiorphan was ass

194 enofovir disoproxil fumarate (TDF) without a protease inhibitor (PI) (0.18 [interquartile range {IQR}

195 osphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were prepared and

196 in vitro and in vivo models to show that HIV protease inhibitor (PI) class ARVs induced neuronal dama

197 We report that GRL-09510, a novel HIV-1 protease inhibitor (PI) containing a newly-generated P2-

198 th was increased, and the sensitivity to the protease inhibitor (PI) lopinavir (LPV) and nucleoside r

199 ith viral load (VL) suppression on a boosted protease inhibitor (PI) regimen, a switch to raltegravir

200 ta on second-line failure and development of protease inhibitor (PI) resistance in sub-Saharan Africa

201 4A protease of the hepatitis C virus lead to protease inhibitor (PI) resistance.

202 itors (NNRTI) SDRMs (1 K101E, 2 K103N) and 1 protease inhibitor (PI) SDRM (M46I).

203 the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resist

204 ensive Care Clinic cohort initiating INSTI-, protease inhibitor (PI)-, and nonnucleoside reverse tran

205 been reported that pregnant women receiving protease inhibitor (PI)-based combination antiretroviral

206 stance in patients who are not responding to protease inhibitor (PI)-based regimens in resource-limit

207 The impact of remaining on failing protease inhibitor (PI)-containing regimens is unclear.

208 deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravi

209 biopsies in patients switching from boosted protease inhibitor (PI/r)-based therapy to dolutegravir

210 as divided into interferon (IFN; 2003-2010), protease inhibitor (PI; 2011-2013), and direct-acting an

211 iptase Inhibitors (EFV) or ritonavir-boosted Protease Inhibitors (PI) with the same backbone of Nucle

212 ubtypes and contributes to susceptibility to protease inhibitors (PI), a critical class of antiretrov

213 5B inhibitor) combined with simeprevir (SIM; protease inhibitor [PI]); however, supporting evidence i

214 Protease inhibitors (PIs) are important components of tr

215 nd X-ray structural analysis of hybrid HIV-1 protease inhibitors (PIs) containing bis-tetrahydrofuran

216 ting antivirals against HCV including NS3/4A protease inhibitors (PIs) has greatly improved treatment

217 everse transcriptase inhibitors (NRTIs), and protease inhibitors (PIs) using Stanford HIVDB 8.8 and S

218 HIV-1-specific nonnucleoside RTIs (NNRTIs), protease inhibitors (PIs), and integrase inhibitors (IIs

219 HIV-1 protease inhibitors (PIs), such as darunavir (DRV), are

220 f Gag in establishing resistance of HIV-1 to protease inhibitors (PIs), very limited data are availab

221 erse transcriptase inhibitors (NNRTIs) and 2 protease inhibitors (PIs).

222 s than 400 copies per mL; p=0.003 versus the protease inhibitor plus NRTI group at 144 weeks.

223 alysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of le

224 plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor

225 r plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or

226 NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per da

227 Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative se

228 In the primary analysis, protease inhibitor plus raltegravir did not meet non-inf

229 per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0.07; lower

230 itor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease

231 INTERPRETATION: Protease inhibitor plus raltegravir offered no advantage

232 ption offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcrip

233 It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidne

234 ven different hydrolases (e.g. alpha-amylase/protease inhibitors preventing both early germination an

235 ther darunavir, the most commonly prescribed protease inhibitor, protects kidneys from HIV-induced in

236 The cyclic peptides reported here as DENV protease inhibitors provide novel scaffolds that enable

237 as the serum cytokines, secretory leukocyte protease inhibitor, regenerating islet-derived protein 3

238 disoproxil fumarate compared with a boosted protease inhibitor regimen of ritonavir-boosted atazanav

239 reduced use of expensive second-line boosted protease inhibitor regimens, this policy option is also

240 In vitro, cysteine protease inhibitors restored granularity, demonstrating

241 The intracellular protease inhibitor Sb9 (SerpinB9) is a regulator of the

242 Using protease inhibitor screening and biochemical analyses, m

243 phil apoptosis and efferocytosis in a serine-protease inhibitor-sensitive manner.

244 Many members of the serine protease inhibitor (serpin) family are activated by glyc

245 eted proteins Fibronectin 1 (FN1) and serine protease inhibitor (serpin) family E member 2 (SERPINE2)

246 tivator inhibitor type-1 (PAI-1) is a serine protease inhibitor (serpin) implicated in numerous patho

247 en activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) that regulates fibrinolysis,

248 t encodes the C1 inhibitor (C1INH), a serine protease inhibitor (serpin).

249 Genetic ablation of serine protease inhibitor SerpinB9 (Sb9) results in the death o

250 ed to determine if S-glutathionylated serine protease inhibitors (serpins) in blood could be used as

251 (GDF15), stanniocalcin 1 (STC1), and serine protease inhibitors (SERPINs), which significantly corre

252 ne peptide isostere developed as an aspartic protease inhibitor shows that it is a flexible architect

253 study that evaluated simeprevir (HCV NS3/4A protease inhibitor) + sofosbuvir (HCV nucleotide analogu

254 reverse transcriptase inhibitor-sparing and protease inhibitor-sparing alternative to three-drug reg

255 interleukin-6 receptor (IL6R), cell surface protease inhibitor Spint-1, the collagen receptor tyrosi

256 Serine protease inhibitors (SPIs) regulate protease-mediated ac

257 rmation) were randomly assigned to a boosted protease inhibitor (standardised to ritonavir-boosted lo

258 ced susceptibility to DAAs, including NS3/4A protease inhibitors such as voxilaprevir.

259 Protease inhibitors, such as trypsin inhibitor, serum al

260 maspin-a noninhibitory member of the serine protease inhibitor superfamily-translocates from the cyt

261 croorganisms as plants with higher levels of protease inhibitors tend to exhibit increased resistance

262 d graded concentration-prophylaxis profiles, protease inhibitors tended to switch between none- and c

263 opeptides are homologous to the I9 family of protease inhibitors that have only been described in fun

264 particular, we found a transient increase in protease inhibitors that inversely correlated with disea

265 Serpins are a family of serine protease inhibitors that regulate proteases of plasma, m

266 n addition, increased expression of a serine protease inhibitor, the hepatocyte growth factor activat

267 pilot screening of a collection of 130 known protease inhibitors, the AlphaLISA assay confirmed all 1

268 ructure similar to a larger family of serine protease inhibitors, the Bowman-Birk inhibitors.

269 ng infection and to assess the efficacy of a protease inhibitor therapy targeting neutrophil elastase

270 s led to several strategies to improve viral protease inhibitors to counter resistance, such as explo

271 the generation of the most potent human HTRA protease inhibitors to date.

272 cular modelling suggested lower affinity for protease inhibitors to HIV-1C protease than to HIV-1B.

273 used a high-throughput screen for Zika virus protease inhibitors to identify several inhibitors of Zi

274 S glycoprotein, we evaluated the ability of protease inhibitors to suppress S glycoprotein function.

275 irrhosis, prior decompensation, and previous protease inhibitor treatments were less likely to achiev

276 Rationale: The role of PI (protease inhibitor) type Z heterozygotes and additional

277 thought of as a functionally self-contained protease inhibitor unit.

278 ract enriched with patatin (up to 60.0%) and protease inhibitors (up to 72.0%), respectively.

279 are-root cells, 1.11 to 2.06; p=0.0089), and protease inhibitor use (3.26, 1.04 to 10.23; p=0.039; mo

280 eb-response system and stratified by boosted protease inhibitor use at baseline.

281 r body mass index with higher ATX, and HIV-1 protease inhibitor use with higher sCD14 levels.

282 alphaM protease inhibitors use theirs to conjugate proteases an

283 a-1 antitrypsin (AAT; Prolastin-C), a serine protease inhibitor used for the treatment of AAT deficie

284 vir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matchi

285 and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-

286 th or without the nonstructural protein 3/4A protease inhibitor voxilaprevir.

287 TMPRSS2, but Zhou et al. found that a serine protease inhibitor was more protective than a cathepsin

288 ccumulation of the cysteine-rich Bowman-Birk protease inhibitor was several fold higher in transgenic

289 erized apoplastic effector EPIC1, a cysteine protease inhibitor, was also secreted from haustoria.

290 ed from a diverse library of internal serine protease inhibitors, was originally designed as a comple

291 xidative regulators, complement proteins and protease inhibitors were enriched in PLS-DA significant

292 es were stable over 2 h after collection and protease inhibitors were not necessary, as no formation

293 2 diabetes mellitus, and nelfinavir, an HIV protease inhibitor, when used alone or in combination.

294 upeptin, elastatinal, and microbial alkaline protease inhibitor, which have been widely used for over

295 SLPI is a secreted serine protease inhibitor, which is overexpressed in a number o

296 the development of novel metal ion-dependent protease inhibitors, which might help to fight bacterial

297 old in the presence of ritonavir-boosted HIV protease inhibitors, while pibrentasvir concentrations w

298 176 (89%) of 198 patients prescribed a protease inhibitor with no predicted-active NRTIs had vi

299 A regimen of protease inhibitor with NRTIs remains the best standardi

300 ecific serpin inhibitor, protein Z-dependent protease inhibitor (ZPI), complexed with its cofactor, p